直接抗病毒药物时代精准临床检测在丙型肝炎患者全程管理中的作用

吴丹; 李智伟

doi:10.3969/j.issn.1001-5256.2017.06.008

直接抗病毒药物时代精准临床检测在丙型肝炎患者全程管理中的作用

DOI: 10.3969/j.issn.1001-5256.2017.06.008

吴丹,
李智伟

中国医科大学附属盛京医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2514
- HTML全文浏览量: 12
- PDF下载量: 493
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents

Wu Dan,
Li ZhiWei

摘要

摘要: HCV感染是全球重要的公共卫生问题。直接抗病毒药物(DAA)已成为减少HCV感染的重要手段。此类药物能提高抗病毒治疗的疗效、缩短疗程、减少并发症出现,并且适用范围更广,具有以往治疗方法不可比拟的优势。在DAA治疗的背景下,精准临床诊断的作用及意义变得尤为重要,为慢性丙型肝炎患者在疾病诊断、治疗方案的确定、疗效评价以及停药后长期预后监测等方面提供了全程保障。
- 肝炎病毒属 /
- 抗病毒药 /
- 诊断
Abstract: Hepatitis C virus (HCV) infection is an important public health issue around the world. Direct-acting antiviral agents (DAAs) have become an important method to reduce HCV infection. DAAs can improve the clinical outcome of antiviral therapy, shorten the course of treatment, and reduce complications and have a wide range of application; therefore, they have great advantages over conventional therapies. Accurate clinical diagnosis has increasing importance in the era of DAAs and guarantees the whole management process of chronic hepatitis C patients from the aspects of disease diagnosis, therapeutic regimens, outcome evaluation, and long-term prognosis monitoring.
- hepacivirus /
- antiviral agents /
- diagnosis

HTML全文

参考文献(30)

[1]KOWDLEY KV, LAWITZ E, POORDAD F, et al.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1[J].N Engl J Med, 2014, 370 (3) :222-232.

[2]SULKOWSKI MS, GARDINER DF, RODRGUEZ-TORRES M, et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].N Engl J Med, 2014, 370 (3) :211-221.

[3]PAWLOTSKY JM.New hepatitis C therapies:the toolbox, strategies, and challenges[J].Gastroenterology, 2014, 146 (5) :1176-1192.

[4]CHAYAMA K, HAYESAYES CN, OHISHI W, et al.Treatment of chronic hepatitis C virus infection in Japan:update on therapy and guidelines[J].J Gastroenterol, 2013, 48 (1) :1-12.

[5]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2014[J].J Hepatol, 2014, 61 (2) :373-395.

[6]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.

[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[8]GOWER E, ESTES C, BLACH S, et al.Global epidemiology and genotype distribution of the hepatitis C virus infection[J].J Hepatol, 2014, 61 (Suppl 1) :s45-s57.

[9]SMITH DB, BUKH J, KUIKEN C, et al.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment web resource[J].Hepatology, 2014, 59 (1) :318-327.

[10]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.

[11]THOMAS DL.Global control of hepatitis C:where challenge meets opportunity[J].Nat Med, 2013, 19 (7) :850-858.

[12]LIANG TJ.Current progress in development of hepatitis C virus vaccine[J].Nat Med, 2013, 19 (7) :869-878.

[13]MAO YL, WANG H, LI BA.HCV laboratory detection and clinical application[J].Infect Dis Info, 2014, 25 (2) :75-79. (in Chinese) 毛远丽, 王晗, 李伯安.HCV实验室检测方法与临床应用[J].传染病信息, 2014, 25 (2) :75-79.

[14]LIU SL.Detection of HCV core antigen in the diagnosis of hepatitis C[J].Continuing Med Education, 2014, 28 (4) :44-46. (in Chinese) 刘胜林.丙肝病毒核心抗原的检测在诊断丙肝中的意义[J].继续医学教育, 2014, 28 (4) :44-46.

[15]LIAO BJ, ZHOU YC, XIE ZC, et al.Clinical application evaluation of some kinds of method in the detection of HCV antibody[J].J Mod Lab Med, 2012, 27 (4) :106-107. (in Chinese) 廖冰洁, 周迎春, 谢在春, 等.几种丙肝抗体检测的临床应用评价[J].现代检验医学杂志, 2012, 27 (4) :106-107.

[16]LI MX, WANG XL, WU XK, et al.Comparative study on the detection of HCV-antigen, HCV-RNA and HCV-antibody detection[J].J Mod Lab Med, 2012, 27 (4) :55-56. (in Chinese) 李妙羡, 王香玲, 吴晓康, 等.HCV抗原检测与HCV-RNA和HCV抗体检测的比较研究[J].现代检验医学杂志, 2012, 27 (4) :55-56.

[17]SIMMONDS P, HOL MES EC, CHA TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region[J].J Gen Virol, 1993, 74 (Pt11) :2391-2399.

[18]YANG R, CONG X, DU S, et al.Performance comparison of the versant HCV genotype 2.0 assay (Li PA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6[J].J Clin Microbiol, 2014, 52 (10) :3685-3692.

[19]ABE H, HAYES CN, HIRAGA N, et al.A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing[J].Am J Gastroenterol, 2013, 108 (9) :1464-1472.

[20]LARRAT S, VALLET S, DAVID-TCHOUDA S, et al.Naturally occurring resistance associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin[J].J Clin Microbiol, 2015, 53 (7) :2195-2202.

[21]European Association for Study of Liver;Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH clinical practice guidelines:non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.

[22]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.

[23]LONG L, LIU Y, DUAN ZJ, et al.A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status[J].Chin J Hepatol, 2015, 22 (4) :244-250. (in Chinese) 龙璐, 刘媛, 段昭君, 等.抗HCV抗体水平在不同HCV感染人群中的临床意义评价[J].中华肝脏病杂志, 2015, 22 (4) :244-250.

[24]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with dacaltasvir plus sofobuvir in patients with hepatitis C virus genetype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.

[25]LONTOK E, HARRINGTON P, HOWE A, et al.Hepatitis C virus drug resistance-associated substitutions:state of the art summary[J].Hepatology, 2015, 62 (5) :1623-1632.

[26]LAWITZ E, SULKOWSKI MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.

[27]LAWITZ E, POORDAD FF, PANG PS, et al.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-na6ve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR) :an open-label, randomized, phase 2 trial[J].Lancet, 2014, 383 (9916) :515-523.

[28]UCHIDA Y, KOUYAMA J, NAIKI K, et al.Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evalued using cycling-probe real-time PCR combined with direct sequencing[J].J Gastroenterol, 2015, 51 (3) :260-270.

[29]SUSSER S, DIETZ J, VERMEHREN J, et al.European RAVs database:frequency and characteristics of RAVs in treatment naive and DAA-experienced patients[J].J Hepatol, 2016, 64 (Suppl2) :s139.

[30]MAASOUMY B, VERMEHREN J, WELKER MW, et al.Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens[J].J Hepatol, 2016, 65 (3) :473-482.

施引文献

资源附件(0)

访问统计